CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 143 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246 | +2.1% | 21,074 | +17.1% | 0.00% | – |
| Q2 2023 | $241 | -37.2% | 17,996 | -22.4% | 0.00% | -100.0% |
| Q1 2023 | $384 | -48.5% | 23,178 | -42.3% | 0.00% | 0.0% |
| Q4 2022 | $746 | -99.7% | 40,158 | +73.6% | 0.00% | – |
| Q3 2022 | $296,000 | +86.2% | 23,126 | +1.8% | 0.00% | – |
| Q2 2022 | $159,000 | -72.7% | 22,708 | -67.7% | 0.00% | -100.0% |
| Q1 2022 | $582,000 | +1087.8% | 70,275 | +853.0% | 0.00% | – |
| Q4 2021 | $49,000 | +6.5% | 7,374 | -16.3% | 0.00% | – |
| Q3 2021 | $46,000 | -53.5% | 8,815 | -59.2% | 0.00% | – |
| Q1 2021 | $99,000 | +86.8% | 21,583 | +18.8% | 0.00% | – |
| Q3 2020 | $53,000 | +1.9% | 18,161 | +59.7% | 0.00% | – |
| Q2 2020 | $52,000 | +6.1% | 11,370 | -10.7% | 0.00% | – |
| Q1 2020 | $49,000 | +250.0% | 12,730 | +237.7% | 0.00% | – |
| Q4 2019 | $14,000 | – | 3,770 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 252,199 | $749,000 | 2.35% |
| MANGROVE PARTNERS IM, LLC | 3,031,965 | $9,005,000 | 1.14% |
| ARMISTICE CAPITAL, LLC | 10,000,000 | $29,700,000 | 1.08% |
| GABLES CAPITAL MANAGEMENT INC. | 432,864 | $1,286,000 | 0.83% |
| Worth Venture Partners, LLC | 268,682 | $798,000 | 0.66% |
| XTX MARKETS LLC | 18,749 | $56,000 | 0.27% |
| Capital Impact Advisors, LLC | 203,133 | $603,000 | 0.18% |
| Wealthspire Advisors, LLC | 337,770 | $1,003,000 | 0.06% |
| ROYCE & ASSOCIATES LP | 1,784,890 | $5,301,000 | 0.06% |
| XML Financial, LLC | 40,000 | $119,000 | 0.04% |